Xin Chen, PhD
|
Title(s) | Professor, Bioengineering |
---|
School | School of Pharmacy |
---|
Address | 513 Parnassus Ave, MSB San Francisco CA 94117
|
---|
Phone | 415-502-6526 |
---|
vCard | Download vCard |
---|
|
|
Biography | 1991 | | First Prize Award, Beijing Medical University, Beijing, China | | 1998 | | Postdoctoral Fellowship Award, Life Science Research Foundation, Baltimore, MD |
Overview My lab studies molecular genetics and signaling pathways during hepatic carcinogenesis. Specifically, using genomic approaches including expression arrays and array based CGH, we have identified large numbers of genes which are deregulated during liver cancer development. Using murine models, we are studying how these genetic alterations contribute to malignant transformation and progression in vivo. Our current studies focus on AKT/mTOR and Notch pathways and how they regulate cancer metabolism and cancer cell proliferation. In addition, using the novel mouse models as preclinical models, we are testing the therapeutic potentials of PI3K/mTOR or Notch inhibitors in treating liver cancers.
Research ORNG Applications Bibliographic
Altmetrics Details
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media.
(Note that publications are often cited in additional ways that are not shown here.)
Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication.
Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication.
Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.)
Click a Field or Translation tag to filter the publications.
-
Identifying strategies to target the metabolic flexibility of tumours. Nat Metab. 2020 04; 2(4):335-350.
Méndez-Lucas A, Lin W, Driscoll PC, Legrave N, Novellasdemunt L, Xie C, Charles M, Wilson Z, Jones NP, Rayport S, Rodríguez-Justo M, Li V, MacRae JI, Hay N, Chen X, Yuneva M. PMID: 32694609.
View in: PubMed Mentions:
-
Mammalian Target of Rapamycin Complex 2 Signaling Is Required for Liver Regeneration in a Cholestatic Liver Injury Murine Model. Am J Pathol. 2020 07; 190(7):1414-1426.
Zhou Y, Xu M, Liu P, Liang B, Qian M, Wang H, Song X, Nyshadham P, Che L, Calvisi DF, Li F, Lin S, Chen X. PMID: 32275903.
View in: PubMed Mentions: Fields: Translation: AnimalsCells
-
Publisher Correction: Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2020 Mar 11.
Chen B, Garmire L, Calvisi DF, Chua MS, Kelley RK, Chen X. PMID: 32161375.
View in: PubMed Mentions: Fields:
-
Oncogene-dependent function of BRG1 in hepatocarcinogenesis. Cell Death Dis. 2020 02 04; 11(2):91.
Wang P, Song X, Cao D, Cui K, Wang J, Utpatel K, Shang R, Wang H, Che L, Evert M, Zhao K, Calvisi DF, Chen X. PMID: 32019910.
View in: PubMed Mentions: 2 Fields:
-
SNAI1 Promotes the Cholangiocellular Phenotype, but not Epithelial-Mesenchymal Transition, in a Murine Hepatocellular Carcinoma Model. Cancer Res. 2019 11 01; 79(21):5563-5574.
Xu M, Wang J, Xu Z, Li R, Wang P, Shang R, Cigliano A, Ribback S, Solinas A, Pes GM, Evert K, Wang H, Song X, Zhang S, Che L, Pascale RM, Calvisi DF, Liu Q, Chen X. PMID: 31383647.
View in: PubMed Mentions: 1 Fields: Translation: HumansAnimals
-
The mTORC2-Akt1 Cascade Is Crucial for c-Myc to Promote Hepatocarcinogenesis in Mice and Humans. Hepatology. 2019 11; 70(5):1600-1613.
Xu Z, Xu M, Liu P, Zhang S, Shang R, Qiao Y, Che L, Ribback S, Cigliano A, Evert K, Pascale RM, Dombrowski F, Evert M, Chen X, Calvisi DF, Chen X. PMID: 31062368.
View in: PubMed Mentions: 4 Fields: Translation: HumansAnimals
-
Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis. J Hepatol. 2019 10; 71(4):742-752.
Wang J, Wang H, Peters M, Ding N, Ribback S, Utpatel K, Cigliano A, Dombrowski F, Xu M, Chen X, Song X, Che L, Evert M, Cossu A, Gordan J, Zeng Y, Chen X, Calvisi DF. PMID: 31195063.
View in: PubMed Mentions: 5 Fields: Translation: HumansAnimalsCells
-
Axis inhibition protein 1 (Axin1) Deletion-Induced Hepatocarcinogenesis Requires Intact ß-Catenin but Not Notch Cascade in Mice. Hepatology. 2019 12; 70(6):2003-2017.
Qiao Y, Wang J, Karagoz E, Liang B, Song X, Shang R, Evert K, Xu M, Che L, Evert M, Calvisi DF, Tao J, Wang B, Monga SP, Chen X. PMID: 30737831.
View in: PubMed Mentions: 4 Fields: Translation: AnimalsCells
-
Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans. Gut. 2020 01; 69(1):177-186.
Che L, Chi W, Qiao Y, Zhang J, Song X, Liu Y, Li L, Jia J, Pilo MG, Wang J, Cigliano A, Ma Z, Kuang W, Tang Z, Zhang Z, Shui G, Ribback S, Dombrowski F, Evert M, Pascale RM, Cossu C, Pes GM, Osborne TF, Calvisi DF, Chen X, Chen L. PMID: 30954949.
View in: PubMed Mentions: 16 Fields: Translation: HumansAnimalsCells
-
Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice. Oncogene. 2018 06; 37(24):3229-3242.
Wang J, Dong M, Xu Z, Song X, Zhang S, Qiao Y, Che L, Gordan J, Hu K, Liu Y, Calvisi DF, Chen X. PMID: 29545603.
View in: PubMed Mentions: 13 Fields: Translation: AnimalsCells
-
Hippo Cascade Controls Lineage Commitment of Liver Tumors in Mice and Humans. Am J Pathol. 2018 04; 188(4):995-1006.
Zhang S, Wang J, Wang H, Fan L, Fan B, Zeng B, Tao J, Li X, Che L, Cigliano A, Ribback S, Dombrowski F, Chen B, Cong W, Wei L, Calvisi DF, Chen X. PMID: 29378174.
View in: PubMed Mentions: 6 Fields: Translation: HumansAnimalsCells
-
Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model. Cell Death Dis. 2018 01 18; 9(2):31.
PMID: 29348467.
View in: PubMed Mentions: 5 Fields: Translation: HumansAnimals
-
Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway. Exp Mol Med. 2018 01 05; 50(1):e417.
Xu Z, Hu J, Cao H, Pilo MG, Cigliano A, Shao Z, Xu M, Ribback S, Dombrowski F, Calvisi DF, Chen X. PMID: 29303510.
View in: PubMed Mentions: 6 Fields: Translation: HumansAnimalsCells
-
Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. J Hepatol. 2017 12; 67(6):1194-1203.
PMID: 28733220.
View in: PubMed Mentions: 17 Fields: Translation: HumansAnimalsCells
-
Glucose Catabolism in Liver Tumors Induced by c-MYC Can Be Sustained by Various PKM1/PKM2 Ratios and Pyruvate Kinase Activities. Cancer Res. 2017 08 15; 77(16):4355-4364.
PMID: 28630053.
View in: PubMed Mentions: 19 Fields: Translation: AnimalsCells
-
A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis. Hepatology. 2017 07; 66(1):167-181.
PMID: 28370287.
View in: PubMed Mentions: 22 Fields: Translation: HumansAnimalsCells
-
Both de novo synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells. Liver Int. 2017 01; 37(1):80-89.
PMID: 27264722.
View in: PubMed Mentions: 25 Fields: Translation: HumansAnimalsCells
-
Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans. Hepatology. 2016 06; 63(6):1900-13.
PMID: 26910791.
View in: PubMed Mentions: 19 Fields: Translation: HumansAnimalsCells
-
Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice. Sci Rep. 2016 Feb 09; 6:20484.
PMID: 26857837.
View in: PubMed Mentions: 33 Fields: Translation: HumansAnimalsCells
-
Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans. J Hepatol. 2016 Feb; 64(2):333-341.
PMID: 26476289.
View in: PubMed Mentions: 34 Fields: Translation: HumansAnimalsCells
This graph shows the total number of publications by year. To see the data as text, click here.
This graph shows the total number of publications by year. To return to the graph, click here.
Year | Publications |
---|
2015 | 1 | 2016 | 3 | 2017 | 3 | 2018 | 4 | 2019 | 5 | 2020 | 4 |
This graph shows the number and percent of publications by field.
Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications.
Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written.
To see the data as text, click here.
This graph shows the number and percent of publications by field.
Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications.
Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written.
To see the data as text, click here.
newest
oldest
line numbers
double spacing
all authors
publication IDs
|
Derived automatically from this person's publications.
_
People in Profiles who have published with this person.
_
People who share similar concepts with this person.
_
Search Department
_
|